在多发性硬化症中对免疫学相关基因进行多基因分析,以确定潜在的药物标
Wenhua Li1, Shuaishuai Chai2, Na Zhang1
1Department of Immunology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan 430030, China.
Journal of affective disorders
|September 2, 2025
概括
类似于Fc受体的3 (FCRL3) 是对多发性硬化症 (MS) 的保护因素. 这种与免疫相关的基因
科学领域:
- 免疫遗传学
- 神经免疫学
- 遗传流行病学
背景情况:
- 多发性硬化症 (MS) 是一种慢性中枢神经系统炎症性疾病,涉及脱髓化和免疫失调.
- 免疫功能与多发性硬化病因之间的确切遗传和病理联系尚未完全理解.
研究的目的:
- 系统地调查免疫相关因素与MS易感性之间的因果关系.
- 确定影响患MS风险的特定免疫相关基因.
主要方法:
- 综合全基因组关联研究 (GWAS) 数据与MS GWAS统计数据.
- 使用孟德尔随机化 (MR) 和贝叶斯定位来推断因果关系.
- 使用基于总结数据的门德尔随机化 (SMR) 和两步MR来评估免疫细胞子集的调解.
主要成果:
- 在多种分析 (循环蛋白,血液和大脑表达) 中,Fc受体样3 (FCRL3) 被确定为MS的保护因素.
- FCRL3与减少多发性硬化风险的因果关系得到了MR,SMR和局部化分析的强有力的支持.
- 在原始的CD4+T细胞上,FCRL3的保护作用部分由CD3表达介导.
结论:
- 在MS的发病过程中,Fc类似受体3 (FCRL3) 起着重要的保护作用.
- 这些发现强调了FCRL3作为多发性硬化症免疫疗法的潜在治疗标.
相关概念视频
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


